Starpharma after 22 years, page-30

According to the company there are discussions happening regarding licencing.

According to the CEO the DEP phase 2 Docetaxel trial was going to finish in 2018 - yes 4 years ago and prior to COVID-19 .... see how that works ?


Starpharma is on a whole other level with its milestones, DEP technology platform and development pipeline, and products/revenues.

Is it though .... how about those revenues in the last Quarterly from 3 different SPL7013 products - even some of the positive posters were disappointed (to say the least) after all the fanfare about Vietnam sales etc ? lol

You also assume that the 'cherry picked" DEP case studies published in the Shareholder Updates are a true representation of the entire DEP phase 2 trials currently being conducted in house or in deed the entire DEP platform ... what if they aren't ? How valuable would SPL really be then in that scenario ?


As for this comment ....

I'm jack of all this negativity, based on what? - no reputable evidence.

..... well there is ample evidence that has been posted on here and I don't have all day so I am not going to list it here again - if you don't like people posting facts about the company because they are negative then maybe don't read their posts ?


I also can't wait to see how the boot from the ASX300 is portrayed as 'good' when it is another negative to add to the pile if it happens - I notice some have already started with the "it's no big deal" rhetoric


GLTAH - It is looking more and more like we need it ?